Investigational drug · Phase 2
lacutamab
Also called: IPH4102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "lacutamab"
First trial start
2019
May 22, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "lacutamab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides/Sezary Syndrome
Approved drugs for the same conditions: Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "lacutamab" as an intervention, largest first.
Innate PharmaIndustry
NCT03902184 · 170 participants · Start May 22, 2019 · Primary completion Jan 8, 2026
Drug: IPH4102 · For: Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides/Sezary Syndrome
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 53 sites in all
- Study of Lacutamab in Peripheral T-cell LymphomaActive, not recruiting
The Lymphoma Academic Research OrganisationAcademic, hospital or other
NCT04984837 · 49 participants · Start Oct 5, 2021 · Primary completion Apr 30, 2028
Drug: Lacutamab; Gemcitabine and 1 more · For: Peripheral T Cell Lymphoma; Relapse/Recurrence
Sites: Anderlecht, Belgium; Antwerp, Belgium; Bruges, Belgium · 64 sites in all
Innate PharmaIndustry
NCT05321147 · 20 participants · Start Mar 17, 2022 · Primary completion Nov 19, 2023
Drug: lacutamab · For: Peripheral T Cell Lymphoma
Sites: Birmingham, Alabama; Orange, California; Goshen, Indiana · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.
Sacknovitz Y, Ma R, Bear CM, et al. · Am J Clin Dermatol 2026
- Targeting cutaneous T-cell lymphoma in non-Hodgkin lymphoma: what's new for investigational agents?
Akkad N, Huen A, Iyer SP · Expert Opin Investig Drugs 2026
- Advancements in Cutaneous T-Cell Lymphoma Treatment: Unveiling Novel Therapeutic Avenues and Clinical Implications.
Qureshi Z, Jamil A, Hameed F, et al. · Am J Clin Oncol 2025
- New nonchemotherapy treatment options for cutaneous T-cell lymphomas an update.
Sethi T, Goyal-O'Leary A, Xu S, et al. · Expert Rev Anticancer Ther 2025
- Therapeutic advances for cutaneous T-cell lymphoma.
Bagot M · Br J Dermatol 2025
- Advances in the pharmacological management of cutaneous T-cell lymphoma.
Roccuzzo G, Roggo A, Ramelyte E, et al. · Expert Opin Pharmacother 2024
Also in development for Lymphoma, T-Cell
- TulmimetostatDZR123, Tulmimetostat DL1Phase 23 trials
Novartis · Progressive Metastatic Castrate Resistant Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Advanced Solid Tumor
- STP938Phase 22 trials
Step Pharma, SAS · Lymphoma, B-Cell, Lymphoma, T-Cell, Essential Thrombocythaemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.